1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,840 | 2,020 | 09:55 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Shanghai Junshi Biosciences reports FY results | 1 | Seeking Alpha | ||
| Sa | Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates | 477 | GlobeNewswire (Europe) | SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to... ► Artikel lesen | |
| Fr | Junshi Jumps as Chinese Drugmaker's Losses Almost Halve in 2024 on Booming Cancer Drug Sales | 1 | Yicai Global | ||
| 27.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT | 1 | HKEx | ||
| 27.03. | JUNSHI BIO (01877): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | - | HKEx | ||
| 27.03. | JUNSHI BIO (01877): TERMS OF REFERENCE OF THE COMPLIANCE COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.03. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 27.03. | JUNSHI BIO (01877): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 | 1 | HKEx | ||
| 27.03. | JUNSHI BIO (01877): ESTABLISHMENT OF COMPLIANCE COMMITTEE | - | HKEx | ||
| 27.03. | Junshi Biosciences Announces Toripalimab's Approval in Singapore | 342 | GlobeNewswire (Europe) | SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 26.03. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE HSA FOR MARKETING OF TORIPALIMAB | - | HKEx | ||
| 24.03. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RETURN OF IDLE PROCEEDS USED FOR TEMPORARY ... | - | HKEx | ||
| 24.03. | Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma | 469 | GlobeNewswire (Europe) | SHANGHAI, March 23, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 21.03. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB IN COMBINATION WITH BEVACIZUMAB FOR THE ... | 1 | HKEx | ||
| 20.03. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JS212 RECEIVED THE NOTICE OF APPROVAL FOR CLINICAL TRIAL | 4 | HKEx | ||
| 14.03. | JUNSHI BIO (01877): DATE OF BOARD MEETING | - | HKEx | ||
| 27.02. | JUNSHI BIO (01877): INSIDE INFORMATION - 2024 PRELIMINARY RESULTS | - | HKEx | ||
| 05.02. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JS213 RECEIVED THE NOTICE OF APPROVAL FOR CLINICAL TRIAL | 1 | HKEx | ||
| 23.01. | LEO pharma gains EU rights to Junshi Biosciences' PD-1 inhibitor toripalimab | 1 | PMLiVE | ||
| 21.01. | Leo bags EU rights to Junshi's Loqtorzi, putting marketing muscle behind PD-1 launch | 1 | FiercePharma |
Seite:
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,325 | +1,12 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
| BIOVENTUS | 9,510 | +1,49 % | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen | |
| CG ONCOLOGY | 22,430 | +1,72 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| EVOTEC | 6,015 | +1,86 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
| 89BIO | 7,190 | +5,81 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,760 | +6,04 % | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen | |
| DISC MEDICINE | 48,500 | +2,86 % | Disc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive... ► Artikel lesen | |
| BIONTECH | 83,50 | -2,00 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
| IMMUNOME | 6,710 | +7,36 % | Hedge Fund and Insider Trading News: Michael Hintze, Stanley Druckenmiller, Bill Ackman, Eisler Capital, Immunome Inc (IMNM), and More | ||
| GUBRA | 59,20 | -1,33 % | AKTIONÄR-Depotwert Gubra: Im Sog von Novo Nordisk - Daten voraus | Die Aktie des dänischen Biopharma-Riesen Novo Nordisk fällt und fällt. Der Abverkauf geht auch an kleineren Playern im Adipositas-Bereich nicht spurlos vorbei. So auch beim AKTIONÄR-Depotwert Gubra:... ► Artikel lesen | |
| 2SEVENTY BIO | 4,955 | +0,10 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| BB BIOTECH | 30,550 | -2,55 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 4,425 | -0,11 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors | Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 11,640 | +14,57 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 17,970 | -0,11 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2024 Financial Results | First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib... ► Artikel lesen |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,810 Euro und damit -6,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.
